These projections suggest that premature and sudden lifting of interventions put in place could lead to an earlier secondary peak of COVID-19, which could be flattened by relaxing the interventions gradually.
Researchers reported on the incidence and outcomes of the SARS-CoV-2 infection, which has been linked to COVID-19, in patients with cancer who were treated at a tertiary cancer institution in Wuhan, China.
A study with a small sample size revealed that trastuzumab deruxtecan showed promising activity in multiple HER2-expressing or HER2-mutant solid tumors.
Favorable toxicity profiles and antitumor activity seen in this phase II study of pembrolizumab supports further evaluation of the drug in this patient population.
The European Society for Medical Oncology released key answers to questions about the coronavirus disease 2019 (COVID-19) as it pertains to cancer care.
The FDA has approved a phase III clinical trial to assess the safety and efficacy of intravenous tocilizumab (Actemra) plus standard of care in hospitalized adult patients with severe COVID-19 pneumonia.
In this study, polypharmacy during the 6-month time period pre-IV chemotherapy was highly predictive of post-chemotherapy inpatient hospitalization.
In a webinar, clinical oncologists spoke about the ways that their treatment practices and workplaces have had to change during the coronavirus disease 2019 pandemic and the ways they should continue to change.
The FDA has approved a 420 mg multi-dose vial of trastuzumab-dttb (Ontruzant), a biosimilar referencing trastuzumab (Herceptin).
The FDA Oncology Center of Excellence put out a statement regarding patients with cancer during the coronavirus disease 2019 (COVID-19) pandemic and how they are prioritizing their care.